Vilming S T, Lyberg T, Lataste X
Cephalalgia. 1986 Sep;6(3):181-2. doi: 10.1046/j.1468-2982.1986.0603181.x.
In a double-blind study the efficacy and tolerability of tizanidine was compared with those of carbamazepine in the management of trigeminal neuralgia. Six patients were allocated to treatment with tizanidine and six to carbamazepine. After individual titration the maximum daily doses were 18 mg and 900 mg, respectively. Among the efficacy factors used, the visual analog scale (VAS) and the overall efficacy as assessed by patients and investigator turned out to be the most appropriate. The results indicate that tizanidine was well tolerated, but the effects, if any, were inferior to those of carbamazepine.
在一项双盲研究中，比较了替扎尼定与卡马西平治疗三叉神经痛的疗效和耐受性。6例患者被分配接受替扎尼定治疗，6例接受卡马西平治疗。经过个体化滴定，最大日剂量分别为18毫克和900毫克。在所使用的疗效评估因素中，视觉模拟量表（VAS）以及患者和研究者评估的总体疗效被证明是最合适的。结果表明，替扎尼定耐受性良好，但即便有效果，也不如卡马西平。
